Nucleoside analog inhibitors of hepatitis C viral replication: Recent advances, challenges and trends

Future Medicinal Chemistry

Volumn 1, Issue 8, 2009, Pages 1429-1452

  Furman, Phillip A ^a   Lam, Angela M ^a   Murakami, Eisuke ^a  

^a PHARMASSET INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' C METHYGUANOSINE; 2' C METHYLADENOSINE; 2' DEOXY 2' BETA F 4' AZIDOCYTIDINE; 2' DEOXY 2' BETA HYDROXY 4' AZIDOCYTIDINE; 2' FLUORO 2' DEOXYCYTIDINE; 2' O METHYLCYTIDINE; 4 N HYDROXYCYTIDINE; 4' AZIDOCYTIDINE; 4' AZIDOCYTIDINE 2',3',5' TRIISOBUTYRATE; ANTIVIRUS AGENT; IDX 184; MK 0608; N 3,5' CYCLO 4 (BETA DEXTRO RIBOFURANOSYL) VIC TRIAZOLO[4,5 B]PYRIDINE 5 ONE; NUCLEOSIDE ANALOG; PLACEBO; PRODRUG; PSI 7851; RG 7128; RO 0622; RO 9187; TUBERCIDIN; UNCLASSIFIED DRUG; VALOPICITABINE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEOSIDES; RIBAVIRIN; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 77953463393     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.88     Document Type: Review

References (116)

1. Marcellin P, Boyer N. Transition of care between paediatric and adult gastroenterology. Chronic viral hepatitis. Best Pract. Res. Clin. Gastroenterol. 17, 259-275 (2003).
2. McHutchison JG, Gordon SC, Schiff ER et al. Interferon a-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 339, 1485-1492 (1998).
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon a-2b plus ribavirin compared with interferon a-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
4. Bressanelli S, Tomei L, Roussel A et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl Acad. Sci. USA 96, 13034-13039 (1999).
5. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 6, 937-943 (1999).
6. Ago H, Adachi T, Yoshida A et al. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7, 1417-1426 (1999).
7. Bressanelli S, Tomei L, Rey FA, De Francesco R. Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. J. Virol. 76, 3482-3492 (2002).
8. O'Farrell D, Trowbridge R, Rowlands D, Jager J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J. Mol. Biol. 326, 1025-1035 (2003).
9. Love RA, Parge HE, Yu X et al. Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. J. Virol. 77, 7575-7581 (2003).
10. Wang M, Ng KK, Cherney MM et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 278, 9489-9495 (2003).
11. Biswal BK, Cherney MM, Wang M et al. Crystal structures of the RNA-dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. J. Biol. Chem. 280, 18202-18210 (2005).
12. Dutartre H, Boretto J, Guillemot JC, Canard B. A relaxed discrimination of 2́-O-methyl-GTP relative to GTP between de novo and elongative RNA synthesis by the hepatitis C RNA-dependent RNA polymerase NS5B. J. Biol. Chem. 280, 6359-6368 (2005).
13. Ferron F, Bussetta C, Dutartre H, Canard B. The modeled structure of the RNA dependent RNA polymerase of GBV-C virus suggests a role for motif E in Flaviviridae RNA polymerases. BMC Bioinformatics 6, 255 (2005).
14. Moradpour D, Brass V, Bieck E et al. Membrane association of the RNA-dependent RNA polymerase is essential for hepatitis C virus RNA replication. J. Virol. 78, 13278-13284 (2004).
15. Tomei L, Altamura S, Bartholomew L et al. Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 77, 13225-13231 (2003).
16. Biswal BK, Wang M, Cherney MM et al. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J. Mol. Biol. 361, 33-45 (2006).
17. Di Marco S, Volpari C, Tomei L et al. Interdomain communication in hepatitis C virus polymerase abolished by small molecule inhibitors bound to a novel allosteric site. J. Biol. Chem. 280, 29765-29770 (2005).
18. Sarisky RT. Non-nucleoside inhibitors of the HCV polymerase. J. Antimicrob. Chemother. 54, 14-16 (2004).
19. Koch U, Narjes F. Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase. Infect. Disord. Drug Targets. 6, 31-41 (2006).
20. Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr. Opin. Investig. Drugs. 8, 614-634 (2007).
21. Simmonds P, Bukh J, Combet C et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42, 962-973 (2005).
22. Thibeault D, Bousquet C, Gingras R et al. Sensitivity of NS3 serine proteases from hepatitis C virus genotypes 2 and 3 to the inhibitor BILN 2061. J. Virol. 78, 7352-7359 (2004).
23. Ludmerer SW, Graham DJ, Boots E et al. Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrob. Agents Chemother. 49, 2059-2069 (2005).
24. Tong X, Guo Z, Wright-Minogue J et al. Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors. Biochemistry 45, 1353-1361 (2006).
25. De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv. Drug Deliv. Rev. 59, 1242-1262 (2007).
26. Herlihy KJ, Graham JP, Kumpf R, Patick AK, Duggal R, Shi ST. Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors. Antimicrob. Agents Chemother. 52, 3523-3531 (2008).
27. Qi X, Bae A, Liu S et al. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res. 81, 166-173 (2009).
28. Cubero M, Esteban JI, Otero T et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370, 237-245 (2008).
29. Kieffer TL, Sarrazin C, Miller JS et al. Telaprevir and pegylated interferon-a-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631-639 (2007).
30. Kronenberger B, Zeuzem S. Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors. Curr. Gastroenterol. Rep. 11, 15-21 (2009).
31. Parfieniuk A, Jaroszewicz J, Flisiak R. Specifically targeted antiviral therapy for hepatitis C virus. World J. Gastroenterol. 13, 5673-5681 (2007).
32. Kwong AD, McNair L, Jacobson I, George S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8, 522-531 (2008).
33. Hinrichsen H, Benhamou Y, Wedemeyer H et al. Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients. Gastroenterology 127, 1347-1355 (2004).
34. Dusheiko G, Hezode C, Pol S et al. Treatment of chronic hepatitis C with telaprevir in combination with peginterferon A-2a with or without ribavirin: interim results of the PROVE2 study. Presented at: 43rd Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008.
35. McHutchison JG, Everson G, Gordon SC et al. PROVE1: results from a Phase 2 study of telaprevir with peginterferon a-2a and ribavirin in treatment-naive subjects with hepatitis C. Presented at: 43rd Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008.
36. Pottage J, Lawitz E, Mazur D et al. Short-term antiviral activity and safety of ACH-806 (GS-9132), an NS4A antagonist, in HCV genotype 1 infected individuals. J. Hepatology 46(Suppl. 1), S294 (2007).
37. Afdahl N, Godofsky E, Dienstag J et al. Final Phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Presented at: 55th Annual Meeting of the American Association for the Study of Liver Diseases. Boston, MA, USA, 29 October-2 November 2004.
38. Nelson D, Pockors P, Godofsky E et al. High end-of-treatment response (84%) after 4 weeks of R1626, peginterferon a-2A (40 kDa) and ribavirin followed by a further 44 weeks of peginterferon a-2A and ribavirin. Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver. 2008. Milan, Italy.
39. Beaulieu PL, Tsantrizos YS. Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr. Opin. Investig. Drug 5, 838-850 (2004).
40. Carroll SS, Olsen DB. Nucleoside analog inhibitors of hepatitis C virus replication. Infect. Disord. Drug Targets. 6, 17-29 (2006).
41. Le Pogam S, Seshaadri A, Kosaka A et al. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J. Antimicrob. Chemother. 61, 1205-1216 (2008).
42. McCown MF, Rajyaguru S, Le Pogam S et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob. Agents Chemother. 52, 1604-1612 (2008).
43. Le Pogam S, Seshaadri A, Kang H et al. Low level of resistance and low viral fitness in vitro and absence of resistance mutations in baseline quasispecies may contribut to high barrier to R1626 resistance in vivo. Presented at: 3rd International Workshop on Hepatitis C-Resistance and New Compounds. Boston, MA, USA, 5-6 June 2008.
44. Le Pogam S, Seshaadri A, Kosaka A et al. Lack of R7128 resistance in vivo may contribute to its potent antiviral activity in genotype 1 non-responder HCV patients. Presented at: 3rd International Workshop on Hepatitis C-Resistance and New Compounds. Boston, MA, USA, 5-6 June 2008.
45. Burgers PM, Eckstein F. Absolute configuration of the diastereomers of adenosine 5́-O-(1-thiotriphosphate): consequences for the stereochemistry of polymerization by DNA-dependent RNA polymerase from Escherichia coli. Proc. Natl Acad. Sci. USA 75, 4798-4800 (1978).
46. Hopkins S, Furman PA, Painter GR. Investigation of the stereochemical course of DNA synthesis catalysed by human immunodeficiency virus type 1 reverse transcriptase. Biochem. Biophys. Res. Commun. 163, 106-110 (1989).
47. Carroll SS, Tomassini JE, Bosserman M et al. Inhibition of hepatitis C virus RNA replication by 2́-modified nucleoside analogs. J. Biol. Chem. 278, 11979-11984 (2003).
48. Migliaccio G, Tomassini JE, Carroll SS et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278, 49164-49170 (2003).
49. Tomassini JE, Getty K, Stahlhut MW et al. Inhibitory effect of 2́-substituted nucleosides on hepatitis C virus replication correlates with metabolic properties in replicon cells. Antimicrob. Agents Chemother. 49, 2050-2058 (2005).
50. Eldrup AB, Allerson CR, Bennett CF et al. Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. J. Med. Chem. 47, 2283-2295 (2004).
51. Eldrup AB, Prhavc M, Brooks J et al. Structure-activity relationship of heterobasemodified 2́-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J. Med. Chem. 47, 5284-5297 (2004).
52. Olsen DB, Eldrup AB, Bartholomew L et al. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob. Agents Chemother. 48, 3944-3953 (2004).
53. Carroll SS, Ludmerer S, Handt L et al. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob. Agents Chemother. 53, 926-934 (2009).
54. Tauzin B. Pharmaceutical research continues against infectious diseases with 388 medicinees and vaccines in testing. In: Medicines in Development for Infectious Diseases. PhrMA, DC, USA 1-36 (2007).
55. Butora G, Olsen DB, Carroll SS et al. Synthesis and HCV inhibitory properties of 9-deaza-and 7,9-dideaza-7-oxa-2́-Cmethyladenosine. Bioorg. Med. Chem. 15, 5219-5229 (2007).
56. Pierra C, Amador A, Benzaria S et al. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2́-C-methylcytidine. J. Med. Chem. 49, 6614-6620 (2006).
57. Murakami E, Niu C, Bao H et al. The mechanism of action of b-D-2́-deoxy-2́-fluoro-2́-C-methylcytidine involves a second metabolic pathway leading to b-D-2́-deoxy-2́-fluoro-2́-C- methyluridine 5́-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. 52, 458-464 (2008).
58. Murakami E, Bao H, Ramesh M et al. Mechanism of activation of b-D-2́-deoxy-2́-fluoro-2́-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob. Agents Chemother. 51, 503-509 (2007).
59. Liu-Young G, Kozal MJ. Hepatitis C protease and polymerase inhibitors in development. AIDS Patient Care STDS. 22, 449-457 (2008).
60. Stuyver LJ, McBrayer TR, Whitaker T et al. Inhibition of the subgenomic hepatitis C virus replicon in Huh-7 cells by 2́-deoxy-2́- fluorocytidine. Antimicrob. Agents Chemother. 48, 651-654 (2004).
61. Stuyver LJ, McBrayer TR, Tharnish PM et al. Inhibition of hepatitis C replicon RNA synthesis by b-D-2́-deoxy-2́-fluoro-2́-C- methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. 17, 79-87 (2006).
62. Clark JL, Hollecker L, Mason JC et al. Design, synthesis, and antiviral activity of 2́-deoxy-2́-fluoro-2́-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 48, 5504-5508 (2005).
63. Ma H, Jiang WR, Robledo N et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor b-d-2́-deoxy- 2́-fluoro-2́-Cmethylcytidine (PSI-6130) and identification of a novel active 5́-triphosphate species. J. Biol. Chem. 282, 29812-29820 (2007).
64. Cretton-Scott E, Perigaud C, Peyrottes S et al. In vitro antiviral activity and pharmacology of IDX184, a novel and potent inhibitor of HCV replication. Presented at: 43rd Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008.
65. Clark JL, Mason JC, Hollecker L et al. Synthesis and antiviral activity of 2́-deoxy-2́-fluoro-2́-C-methyl purine nucleosides as inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 16, 1712-1715 (2006).
66. Prhavc M, Dyatkina N, Keicher J et al. Synthesis and biological activity of 7-deaza-7-ethynyl-2́-deoxy-2́-fluoro-2́-Cmethyladenosine and its 2́-C-methyl-ribo analogue. Nucleic Acids Symp. Ser. 643-644 (2008).
67. Standring DN, Lanford R, Cretton-Scott E et al. Potent antiviral activity of second generation nucleoside inhibitors IDX102 and IDX184, in HCV-infected chimpanzees. Presented at: 43rd Meeting of the European Association for the Study of the Liver. Milan, Italy, 23-27 April 2008.
68. Gane E, Rodriguez-Torres M, Nelson D et al. Antiviral activity of the HCV nucleoside polymerase inhibitor R7128 in HCV genotype 2 and 3 prior non-responders: results of R7128 1500mg BID with PEG-IFN and ribavirin for 28 days. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA, USA, 31 October-4 November 2008.
69. Tan H, Sonal R, Wu T et al. Combination of the NS3/4A protease inhibitor ITMN-191 (R7227) with the active moiety of the NS5B inhibitors R1626 or R7128 enhances replicon clearance and reduces the emergence of drug resistant variants. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA, USA, 31 October-4 November 2008.
70. Klumpp K, Leveque V, Le Pogam S et al. The novel nucleoside analog R1479 (4́-azidocytidine) is a potent inhibitor of NS5B-dependent RNA synthesis and hepatitis C virus replication in cell culture. J. Biol. Chem. 281, 3793-3799 (2006).
71. Roberts SK, Cooksley G, Dore GJ et al. Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebocontrolled study in patients with chronic hepatitis C. Hepatology 48, 398-406 (2008).
72. Klumpp K, Kalayanov G, Ma H et al. 2́-deoxy-4́-azido nucleoside analogs are highly potent inhibitors of hepatitis C virus replication despite the lack of 2́-a-hydroxyl groups. J. Biol. Chem. 283, 2167-2175 (2008).
73. Smith DB, Kalayanov G, Sund C et al. The design, synthesis, and antiviral activity of 4́-azidocytidine analogues against hepatitis C virus replication: the discovery of 4́-azidoarabinocytidine. J. Med. Chem. 52, 219-223 (2009).
74. Smith DB, Kalayanov G, Sund C et al. The design, synthesis, and antiviral activity of monofluoro and difluoro analogues of 4́-azidocytidine against hepatitis C virus replication: the discovery of 4́-azido-2́-deoxy- 2́-fluorocytidine and 4́-azido-2́-dideoxy-2́,2́- difluorocytidine. J. Med. Chem. 52, 2971-2978 (2009).
75. Shi J, Du J, Ma T et al. Synthesis and anti-viral activity of a series of d-and l-2́-deoxy-2́-fluororibonucleosides in the subgenomic HCV replicon system. Bioorg. Med. Chem. 13, 1641-1652 (2005).
76. Hernandez-Santiago BI, Beltran T, Stuyver L, Chu CK, Schinazi RF. Metabolism of the anti-hepatitis C virus nucleoside b-d-N4-hydroxycytidine in different liver cells. Antimicrob. Agents Chemother. 48, 4636-4642 (2004).
77. Hollecker L, Choo H, Chong Y et al. Synthesis of beta-enantiomers of N4-hydroxy-3́-deoxypyrimidine nucleosides and their evaluation against bovine viral diarrhoea virus and hepatitis C virus in cell culture. Antivir. Chem. Chemother. 15, 43-55 (2004).
78. Wang P, Hollecker L, Pankiewicz KW et al. Synthesis of N3,5́-cyclo-4-(b-dribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one, a novel compound with anti-hepatitis C virus activity. J. Med. Chem. 47, 6100-6103 (2004).
79. Wang P, Hollecker L, Pankiewicz KW et al. Synthesis of N3,5́-cyclo-4-(b-dribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one and its 3́-deoxysugar analogue as potential anti-hepatitis C virus agents. Nucleosides Nucleotides Nucleic Acids 24, 957-960 (2005).
80. Hassan AE, Wang P, McBrayer T et al. Synthesis and anti-HCV activity of N9,5́-cyclo-3-(b-d-ribofuranosyl)-8-azapurin-2-one derivatives. Nucleosides Nucleotides Nucleic Acids 24, 1531-1542 (2005).
81. Hassan AE, Wang P, McBrayer TR et al. Synthesis and anti-hepatitis C virus activity of nucleoside derivatives of N3, 5́-anhydro-4-(b-d- ribofuranosyl)-8-aza-purin-2-ones. Nucleosides Nucleotides Nucleic Acids 24, 961-964 (2005).
82. Chun BK, Wang P, Hassan A et al. Synthesis and biological activity of 5́,9-anhydro-3-purine-isonucleosides as potential antihepatitis C virus agents. Nucleosides Nucleotides Nucleic Acids 26, 83-97 (2007).
83. Chun BK, Wang P, Hassan A et al. Synthesis of 5́,9-anhydro-3-(b-d- ribofuranosyl) xanthine, and 3,5́-anhydro-xanthosine as potential anti-hepatitis C virus agents. Tetrahedron Lett. 46, 2825-2827 (2005).
84. Hocek M, Naus P, Pohl R et al. Cytostatic 6-arylpurine nucleosides. 6. SAR in anti-HCV and cytostatic activity of extended series of 6-hetarylpurine ribonucleosides. J. Med. Chem. 48, 5869-5873 (2005).
85. Prakash TP, Prhavc M, Eldrup AB et al. Synthesis and evaluation of S-acyl-2-thioethyl esters of modified nucleoside 5́-monophosphates as inhibitors of hepatitis C virus RNA replication. J. Med. Chem. 48, 1199-1210 (2005).
86. Furman PA, Bao D, Chang W et al. b-d-2́-deoxy-2́-fluoro- 2́-C-methyluridine phosphoramidates are potent and selective inhibitors of HCV RNA replication. Presented at: 15th International Symposium on Hepatitis C Virus And Related Viruses. San Antonio, TX, USA, 5-9 October 2008.
87. Sofia MA, Wang P, Du J et al. b-d-2́-deoxy-2́-fluoro- 2́-C-methyluridine phosphoramidates: potent and selective inhibitors of HCV RNA replication. Presented at: 14th International Symposium on Hepatitis C Virus and Related Viruses. Glasgow, Scotland, UK, 9-13 October 2007.
88. Sofia MA, Wang P, Du J et al. b-d-2́-deoxy-2́-fluoro- 2́-C-methyluridine (PSI-6206) phosphoramidates: potent liver targeting nucleoside inhibitors of HCV RNA replication. Presented at: 236th ACS National Meeting. Philadelphia, PA, USA, 18 August 2008.
89. Furman PA, Wang P, Niu C et al. PSI-7851: a novel liver-targeting nucleotide prodrug for the treatment of hepatitis C. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases. San Francisco, CA, USA, 31 October-4 November 2008.
90. Perrone P, Daverio F, Valente R et al. First example of phosphoramidate approach applied to a 4́-substituted purine nucleoside (4́-azidoadenosine): conversion of an inactive nucleoside to a submicromolar compound versus hepatitis C virus. J. Med. Chem. 50, 5463-5470 (2007).
91. Perrone P, Luoni GM, Kelleher MR et al. Application of the phosphoramidate ProTide approach to 4́-azidouridine confers sub-micromolar potency versus hepatitis C virus on an inactive nucleoside. J. Med. Chem. 50, 1840-1849 (2007).
92. Donghi M, Attenni B, Gardelli C et al. Synthesis and evaluation of novel phosphoramidate prodrugs of 2́-methyl cytidine as inhibitors of hepatitis C virus NS5B polymerase. Bioorg. Med. Chem. Lett. 19, 1392-1395 (2009).
93. McGuigan C, Cahard D, Sheeka HM, De Clercq E, Balzarini J. Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite. J. Med. Chem. 39, 1748-1753 (1996).
94. Hecker SJ, Reddy KR, van Poelje PD et al. Liver-targeted prodrugs of 2́-C-methyladenosine for therapy of hepatitis C virus infection. J. Med. Chem. 50, 3891-3896 (2007).
95. Gunic E, Girardet JL, Ramasamy K et al. Cyclic monophosphate prodrugs of base-modified 2́-C-methyl ribonucleosides as potent inhibitors of hepatitis C virus RNA replication. Bioorg. Med. Chem. Lett. 17, 2452-2455 (2007).
96. Lallos L, La Colla M, Soubasakos MA et al. Enhanced antiviral activity of IDX184 in combination with IFN-a RBV or an IDX PI in the HCV replicon model. Presented at: 15th International Symposium on Hepatitis C Virus and Related Viruses. San Antonio, TX, USA, 5-9 October 2008.
97. Le Pogam S, Jiang WR, Leveque V et al. In vitro selected Con1 subgenomic replicons resistant to 2́-C-methyl-cytidine or to R1479 show lack of cross resistance. Virology 351, 349-359 (2006).
98. Ali S, Leveque V, Le Pogam S et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob. Agents Chemother. 52, 4356-4369 (2008).
99. Dutartre H, Bussetta C, Boretto J, Canard B. General catalytic deficiency of hepatitis C virus RNA polymerase with an S282T mutation and mutually exclusive resistance towards 2́-modified nucleotide analogues. Antimicrob. Agents Chemother. 50, 4161-4169 (2006).
100. Uzgiris A, Steuer HM, Eurakami E et al. High genetic barrier to HCV resistance presented by PSI-6130. Presented at: HepDart: Frontiers in Drug Development for Viral Hepatitis. Lahaina, Hawaii, 9-11 December 2007.
101. Kuntzen T, Timm J, Berical A et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48, 1769-1778 (2008).
102. Forns X, Bukh J. The molecular biology of hepatitis C virus. Genotypes and quasispecies. Clin. Liver Dis. 3, 693-716 (1999).
103. Nguyen MH, Keeffe EB. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin Gastroenterol Hepatol. 3, S97-S101 (2005).
104. Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol. 13, 4808-4817 (2007).
105. Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. World J. Gastroenterol. 13, 2461-2466 (2007).
106. Le Guillou-Guillemette H, Vallet S, Gaudy-Graffin C et al. Genetic diversity of the hepatitis C virus: impact and issues in the antiviral therapy. World J. Gastroenterol. 13, 2416-2426 (2007).
107. Pauwels F, Mostmans W, Quirynen LM et al. Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors. J. Virol. 81, 6909-6919 (2007).
108. Heck JA, Lam AM, Narayanan N, Frick DN. Effects of mutagenic and chain-terminating nucleotide analogs on enzymes isolated from hepatitis C virus strains of various genotypes. Antimicrob. Agents Chemother. 52, 1901-1911 (2008).
109. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350-1359 (2006).
110. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment-finding the right path. Nat. Rev. Drug Discov. 6, 991-1000 (2007).
111. Lam AM, Espiritu C, Steuer HM et al. PSI-6130 is synergisitic or additive in combination with HCV protease or polymerase inhibitors in subgenomic replicons. Presented at: 15th International Symposium on Hepatitis C Virus and Related Viruses. San Antonio TX, USA, 5-9 October 2008.
112. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilley J. Prodrugs: Challenges and Rewards. Stella VJ (Ed.). Springer, NY, USA (2007).
113. Erion MD, Reddy KR, Boyer SH et al. Design, synthesis, and characterization of a series of cytochrome P(450) 3A-activated prodrugs (HepDirect prodrugs) useful for targeting phosph(on)ate-based drugs to the liver. J. Am. Chem. Soc. 126, 5154-5163 (2004).
114. Erion MD, van Poelje PD, Mackenna DA et al. Liver-targeted drug delivery using HepDirect prodrugs. J. Pharmacol. Exp. Ther. 312, 554-560 (2005).
115. Erion MD, Bullough DA, Lin CC, Hong Z. HepDirect prodrugs for targeting nucleotidebased antiviral drugs to the liver. Curr. Opin. Investig. Drugs. 7, 109-117 (2006).
116. Pfefferkorn JA, Nugent R, Gross RJ et al. Inhibitors of HCV NS5B polymerase. Part 2: evaluation of the northern region of (2Z)-2-benzoylamino-3- (4-phenoxy-phenyl)-acrylic acid. Bioorg. Med. Chem. Lett. 15, 2812-2818 (2005).